Moseley Investment Management Inc. Trims Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Moseley Investment Management Inc. reduced its stake in Johnson & Johnson by 49.1%, owning 7,098 shares valued at approximately $1,084,000 following the sale of 6,841 shares in the 2nd quarter.
• Several large investors, including Callan Family Office LLC with a 73.5% increase in their holdings, have modified their stakes in Johnson & Johnson during the same period.
• Wall Street analysts have varying ratings on the stock, with a consensus target price of $192.94 and the majority rating it as a "Moderate Buy."

Moseley Investment Management Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 49.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,098 shares of the company's stock after selling 6,841 shares during the period. Moseley Investment Management Inc.'s holdings in Johnson & Johnson were worth $1,084,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Stonebridge Financial Group LLC increased its stake in shares of Johnson & Johnson by 2.0% in the second quarter. Stonebridge Financial Group LLC now owns 37,907 shares of the company's stock worth $5,790,000 after purchasing an additional 736 shares in the last quarter. Horizon Bancorp Inc. IN increased its stake in shares of Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock worth $97,000 after purchasing an additional 64 shares in the last quarter. Callan Family Office LLC increased its stake in shares of Johnson & Johnson by 73.5% in the second quarter. Callan Family Office LLC now owns 56,136 shares of the company's stock worth $8,575,000 after purchasing an additional 23,772 shares in the last quarter. Rice Partnership LLC increased its stake in shares of Johnson & Johnson by 4.3% in the second quarter. Rice Partnership LLC now owns 7,905 shares of the company's stock worth $1,207,000 after purchasing an additional 328 shares in the last quarter. Finally, Mainstay Capital Management LLC ADV increased its stake in shares of Johnson & Johnson by 99.4% in the second quarter. Mainstay Capital Management LLC ADV now owns 4,892 shares of the company's stock worth $747,000 after purchasing an additional 2,439 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on JNJ. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a research note on Monday, October 6th. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Tuesday, September 16th. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $176.00 to $178.00 and gave the company an "equal weight" rating in a research note on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $192.94.

Johnson & Johnson Price Performance

JNJ stock opened at $190.66 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $192.10. The stock has a market cap of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. The firm has a 50 day simple moving average of $178.48 and a two-hundred day simple moving average of $163.77.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion during the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.